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Abstract: Type 2 familial partial lipodystrophy, or Dunnigan disease, is a metabolic disorder char-
acterized by abnormal subcutaneous adipose tissue distribution. This rare condition results from
variants principally affecting exons 8 and 11 of the LMNA gene. In this study, five FPLD2-diagnosed
patients carrying the c.1583C>T, p.(Thr528Met) variant in exon 9 of the LMNA gene and with obvious
clinical heterogeneity were evaluated. Specific polymorphisms in LMNA and in PPARG were also
detected. Exhaustive clinical course, physical examination, biochemical features and family history
were recorded, along with the assessment of anthropometric features and body composition by
dual-energy X-ray absorptiometry. Preadipocytes obtained from a T528M patient were treated with
the classic adipose differentiation medium with pioglitazone. Various adipogenes were evaluated
by real-time PCR, and immunofluorescence was used to study intracellular localization of emerin,
lamin A and its precursors. As demonstrated with Oil red O staining, the preadipocytes of the
T528M patient failed to differentiate, the expression of various adipogenic genes was reduced in the
lipodystrophic patient and immunofluorescence studies showed an accumulation of farnesylated
prelamin A in T528M cells. We conclude that the T528M variant in LMNA could lead to FPLD2, as
the adipogenic machinery is compromised.
Keywords: type 2 familial partial lipodystrophy; FPLD2; LMNA; T528M
1. Introduction
Familial partial lipodystrophies are a group of Mendelian diseases characterized by
the loss of subcutaneous adipose tissue in the lower limbs and sometimes also in the upper
limbs, with abnormal fat accumulation in other regions. Affected subjects have insulin
resistance leading to complications such as diabetes, dyslipidemia, liver steatosis and
increased cardiovascular risk. FPLD2 patients exhibit lipoatrophy in the upper and lower
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limbs and buttocks from puberty, particularly in women, and accumulation of fat in the
neck, face and visceral depots, following an autosomal dominant pattern of inheritance.
FPLD2 results from variants in the LMNA gene (1q21–q23), which codes for type-A
lamins by alternative splicing: lamin A, lamin C, lamin C2 and lamin A∆10. These are inter-
mediate filament proteins, forming polymers at the nuclear lamina, a meshwork underlying
the inner nuclear membrane. They exert recognized functions in a range of transcendental
biological processes: mechanical function in nuclear shape maintenance, conservation
of nuclear and chromatin architecture, DNA replication and transcription, cell cycle and
cellular senescence/apoptosis, cell proliferation, tumor progression and interactions with
other nuclear and cytoplasmatic proteins (thus regulating the communication between
these two compartments).
Type-A lamins have a characteristic structure: a small N-terminal head domain, a
coiled-coil rod domain divided into four α-helix segments, and a globular C-terminal
IgG-like end or tail domain. The rod domain allows coiled-coil dimerization, while the
head and the tail are involved in the end-to-end assembly of the polymer, and greater
associations. The main isoforms of type-A lamins are lamins A and C, both identical to
codon 566, from which lamin C lacks part of the C-terminal region, including some amino
acids of exon 10, exon 11 and exon 12. It is important to note that FPLD is generally caused
by heterozygous amino acid changes in the C-terminal domain of lamin A/C, usually
between exons 8 and 11 (>90% of variants affect codon 482 of the gene, a mutational hot
spot). These regions codify for the protein elements involved in prelamin A processing to
generate mature lamin A.
Previous studies have suggested that variant c.1583C>T, p.(Thr528Met) only produces
pathological manifestations when it appears in compound heterozygosity [1,2]. We report
here the cases of five patients from four pedigrees with clinical diagnosis of FPLD2, carrying
the p.(Thr528Met) missense variant in exon 9 of the LMNA gene. Various genes related to
other forms of familial partial lipodystrophies were also analyzed by NGS (next-generation
sequencing). The primary objective of this study was to clearly establish that this LMNA
variant is the primary cause of the lipodystrophy observed in our patients by evaluating
whether it alters adipogenesis in human preadipocytes. No less important was the aim to
examine the complex genotype-phenotype associations in more depth along with the wide
clinical heterogeneity observed.
2. Experimental Section
This study was approved by the Ethics Review Panel of Xunta de Galicia, and carried
out according to the ethical guidelines of the Helsinki Declaration. Patients gave informed
consent for participation in the study and the publication of clinical, biochemical, and
genetic information.
2.1. Subjects, Analysis and Interpretation of Variants
All patients studied are heterozygous for the variant c.1583C>T, p.(Thr528Met) in
the LMNA gene. The search for variants in genes AGPAT2, AKT2, BANF1, BLM, BSCL2,
CAV1, CIDED, ERCC6, ERCC8, FBN1, KCNJ6, LIPE, PCYT1A, PIK3R1, PLIN1, POLD1,
PPARG, PSMB8, PTRF, SPRTN, WRN and ZMPSTE24 was made by NGS (Ion torrent
System, Thermo Fisher Scientific, Waltham, MA, USA) sequencing of the entire coding
region of the genes and the flanking intronic regions. The capture of the regions of interest
was performed using SureSelectXT Custom (Agilent, St Clara, CA, USA) and data analysis
was performed using computer tools: TMAP 5.4.11, TVC 5.4–11, GATK v3.8–0, Picard
2.10.2-SNAPSHOT, BEDtools v2.26.0, SAMtools 1.5 and ExomeDepth 1.1.10. Interpretation
of classification of variants was done by following the guidelines of the American College
of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG,
Bethesda, MD, USA) [3]. The classification of the variants identified reflects the current
state of scientific knowledge and they might change as new scientific information becomes
available. Different resources and databases were used for the variant classification as
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Varsome [4], gnomAD [5] (https://gnomad.broadinstitute.org, accessed 2 April 2021),
ClinVar [6] and dbSNP [7].
2.2. Body Composition Studies
Height and body weight were measured by standard procedures. Skinfold thicknesses
were measured with Lange Skinfold calipers (Cambridge Scientific Industries, Watertown,
MA, USA) at two truncal (subscapular and suprailiac) and four peripheral sites (biceps,
triceps, thigh and calf) on the right side of the body. The distribution of body fat was
assessed via whole-body dual-energy X-ray absorptiometry (DXA), using a Lunar model
DPX apparatus (GE Healthcare Lunar, Madison, WI, USA) [8].
2.3. Biochemical Analyses
Fasting serum samples were analyzed for glucose, total cholesterol, HDL-cholesterol,
LDL-cholesterol, triglycerides, thyroid stimulating hormone (TSH), creatinine, and creatine
kinase (CK) as described previously [9]. Glycated hemoglobin (HbA1c) was measured
using ion-exchange high-performance liquid chromatography (Bio-Rad Laboratories Inc.,
Hercules, CA, USA). Aspartate aminotransferase (AST), alanine aminotransferase (ALT)
and gamma-glutamyl transpeptidase (GGT) were determined with enzymatic methods on
an ADVIA analyzer (Siemens, Bayer Diagnostics, Tarrytown, NY, USA). Plasma insulin
concentrations were determined in duplicate by chemiluminescence, using a commercial
kit (Nichols Institute, San Juan Capistrano, CA, USA). Plasma leptin levels and C-peptide
were determined by ELISA assay (DRG International, Inc., Springfield, NJ, USA).
2.4. Adipose Tissue Biopsies and Cell Culture
A small sample of subcutaneous adipose tissue was obtained from the lower back
area of Case #1 at 42 years of age. A control of normal adipose tissue sample was obtained
from the back of a 32-year-old woman who underwent programmed surgery for lipoma
extraction, in accordance with current Spanish legislation. Small pieces of adipose tis-
sue were placed on a 60 mm dish (BD FalconTM; Mississauga, ON, Canada) containing
Dulbecco’s modified Eagle’s medium (DMEM) plus 30% fetal bovine serum (FBS) and
gentamicin 50 µg/mL, and incubated at 37 ◦C with 5% CO2 in a Water-Jacket CO2 incu-
bator (NuAire; Plymouth, MN, USA). Preadipocytes were recognized by the presence of
small lipid droplets in the fibroblast-like cells using a phase microscope. Subsequently,
these preadipocytes were trypsinized (TrypLE™ Express Stable Trypsin-like Enzyme with
Phenol Red; Gibco Life Technologies; Carlsbad, CA, USA) and cultured on 100 mm dishes
in DMEM containing 10% FBS and penicillin-streptomycin 1%.
2.5. Adipocyte Differentiation Procedure
After confluence, preadipocytes were cultured on 35 mm multi-well dishes (6-well
plates) in a differentiation cocktail containing Dulbecco’s modified Eagle’s medium plus
10% fetal bovine serum, insulin (1 µg/mL), dexamethasone (0.25 µM) and 3-isobutyl-1-
methylxanthine (0.1 mM in DMSO) [10] for 3 days, with a PPARG agonist, pioglitazone
(10 µM in DMSO; Alexis Biochemicals, Lausanne, Switzerland), after which this medium
was changed for a growth medium containing 1 µg/mL insulin with pioglitazone (10 µM)
for two more days. The cells were then left to differentiate for another 5 days with growth
medium containing pioglitazone (10 µM) changed every other day. Non-differentiated
preadipocytes were supplemented with equivalent concentrations of DMSO and used
as controls.
2.6. Phase Contrast Microscopy
Cells were fixed in 10% formalin for 60 min at room temperature, washed three times
with distilled water and then stained with 0.5% (w/v) Oil red O solution in 60% isopropanol
for 60 min, at 22 ◦C. Cells were washed again three times with distilled water, and lipid
accumulation was finally estimated by phase contrast microscopy.
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2.7. RNA Extraction and Retrotranscription
Total RNA was extracted from preadipocytes, using TRIzol (Invitrogen, Madrid, Spain)
as per the manufacturer’s instructions. RNA was reverse-transcribed by using M-MLV
reverse transcriptase (Invitrogen) as previously described [11].
2.8. Real-Time PCR
Specific primers and probes designed by Universal Probe Library (Roche Diagnostics,
Sant Cugat del Valles, Spain; Table 1) were used to determine the specific expression of
CEBPA, CEBPB, FABP4, GLUT4, LPL, and PPARG and PREF-1 genes in a Light Cycler
2.0 (Roche Diagnostics). Real-time PCR conditions are available upon request. Results
were normalized for the internal control RNA polymerase II gene, using the 2-∆∆ CT
method [12].
Table 1. Primer sequences and probes.




CEBPA GCAAATCGTGCCTTGTCAT CTCATGGGGGTCTGCTGTAG 12 CTCCTTCC 72
CEBPB CGCTTACCTCGGCTACCA ACGAGGAGGACGTGGAGAG 74 CTGCTGCC 65
FABP4 CCTTTAAAAATACTGAGATTTCCTTCA GGACACCCCCATCTAAGGTT 72 TTCCTGGC 105
GLUT4 CTGTGCCATCCTGATGACTG CGTAGCTCATGGCTGGAACT 67 TGCTGGAG 62
LPL ATGTGGCCCGGTTTATCA CTGTATCCCAAGAGATGGACATT 25 CTCCTCCA 76
PPARG GACCTGAAACTTCAAGAGTACCAAA TGAGGCTTATTGTAGAGCTGAGTC 39 CTCCACCT 95
PREF-1 GACGGGGAGCTCTGTGATAG CATAGAGGCCATCGTCCAG 68 AGGAGCAG 94
RNA polymerase II GCATCATGAACAGCGATGAG TCATCCATCTTGTCCACCAC 69 GGAGGAAG 64
2.9. Immunofluorescence
Cells grown on glass coverslips were fixed with 4% paraformaldehyde, at 4 ◦C, for 1 h,
and permeabilized in 0.1% Triton X-100, at room temperature for, 10 min. After blocking
for non-specific binding (4% BSA, 1 h, at room temperature), the coverslips were incubated
in an appropriate primary antibody, at 4 ◦C, overnight (1:150 anti-prelamin A (ANT0045,
Diatheva, Fano, Italy), 1:120 anti-farnesylated prelamin A (ANT0046, Diatheva, Fano,
Italy), 1:50 anti-emerin (Novocastra Leica, Barcelona, Spain) and 1:100 anti-lamin A/C
(N-18) (Santa Cruz Biotechnology, Heidelberg, Germany)). The ANT0045 does not bind
carboxymethylated-farnesylated prelamin A, while no cross-reaction is observed between
ANT0046 and full-length prelamin A [13]. The following day, after three washes, the cover-
slips were incubated for 1 h, at room temperature, in darkness, with 1:600 Cy2-AffiniPure
F(ab’)2 Fragment and 1:600 Cy3-AffiniPure F(ab’)2 Fragment (Jackson Immunoresearch,
West Grove, PA, USA) and counterstained with 1:1000 DAPI (Life Technologies, Madrid,
Spain). Coverslips were mounted in Fluoromount medium (Sigma, Barcelona, Spain).
Immunofluorescence staining was analyzed using an Olympus IX51 microscope (Olympus
Corporation) equipped with an Olympus DP72 digital camera.
2.10. Statistical Analysis
Real-time PCR analyses were performed by triplicates. Statistical significance was
determined by using a non-parametric Kruskal-Wallis test, followed by a Mann-Whitney
U post hoc Bonferroni’s correction. Data are presented as mean ± standard deviation (SD),
with statistical significance set at p < 0.05, and were evaluated by using SPSS for PC (release
22; SPSS, Chicago, IL, USA).
3. Results
Photographs of the studied subjects, pedigrees and color map of DXA scans are
depicted in Figures 1–3, respectively. Demographic, anthropometric, biochemical and
clinical features are summarized in Table 2.
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Figure 1. Photographs of the five cases with FPLD2 bearing the p.(Thr528Met) variant in the LMNA gene. The photographs 
show body morphology caused by the p.(Thr528Met) variant. (A) Case #1 is a 53-year-old female. Fat loss higher than in Figure 1. Photographs of the five cases with FPLD2 bearing the p.(Thr528Met) variant in the LMNA
gene. The photographs show body morphology caused by the p.(Thr528Met) variant. (A) Case #1 is
a 53-year-old female. Fat loss higher than in the other patients. Lack of subcutaneous adipose tissue
in limbs, abdomen and buttocks. Rounded face, double chin, hypermuscular appearance with calf
hypertrophy, hepatomegaly, phlebomegaly and small breasts. (B) Case #2 is a 58-year-old female. Fat
loss in upper limbs, hips, thighs and calves. Fat accumulation in face with double chin, in upper back
and intra-abdominal region. Scarce abdominal subcutaneous adipose panicle. Phlebomegaly. Calf
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hypertrophy. Acanthosis nigricans on the nape and axillae. Hepatomegaly, splenomegaly. (C) Case
#3 is a 34-year-old female. No obvious fat loss. Low fat in arms, buttocks, hips and lower extremities.
Fat accumulation in face, double chin, trunk, abdomen and axillae. Minimal acanthosis nigricans.
(D) Case #4 is a 20-year-old female. Fat accumulation in face, double chin, dorsal region, axillae,
neck, arms and scapular region. Scarce fat in hips, buttocks, thighs and calves. Phlebomegaly and
marked musculature in lower limbs. Normal amount of fat in abdomen and upper limbs. Hirsutism.
Acanthosis nigricans in axillae, nape and groin areas. (E) Case #5 is a 62-year-old female. Fat loss in
upper limbs, lower limbs, buttocks and hips. Accumulation of fat in face, abdomen, chin, back and
axillae. Well-defined muscles in arms, legs and buttocks. Minimal phlebomegaly in arms.
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filled orange symbols. Squares denote males, and circles denote females. Circles and squares with a diagonal slash denote 
deceased subjects. The inheritance pattern was autosomal dominant in a vertical way. 
 
Figure 2. Pedigrees of the four families with FPLD2 due to the p.(Thr528Met) variant. Genograms.
Affected individuals with the LMNA p.(Thr528Met) variant and the LMNA p.(Ser573Leu) variant
are shown as half-filled red and blue symbols, respectively, unaffected subjects as unfilled symbols,
individuals for whom the phenotype is suspected are shown as half-filled orange symbols. Squares
denote males, and circles denote females. Circles and squares with a diagonal slash denote deceased
subjects. The inheritance pattern was autosomal dominant in a vertical way.
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Figure 3. DXA scans of patients with the p.(Thr528Met) and p.(Arg482Trp) variants in the LMNA gene and control subjects.
The total body scans were color-mapped, with green representing an area of low level % fat (0–25%), yellow an area of
medium level % fat (25–60%) and red an area of high level % fat (60–100%).
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Table 2. Demographic, anthropometric, biochemical and clinical features of the studied subjects.
Demographic Features
Case #1 Case #2 Case #3 Case #4 Case #5
Age 42.8 53.8 34.7 18.1 62.1
























inheritance yes yes yes yes yes
SNP PPARGp.Pro12Ala yes no no no no
Clinical features
Acanthosis no yes yes yes no
Phlebomegaly no yes no yes yes
Hypermuscularity yes yes no no yes
Lipomas no no yes no no
Goiter no no no no yes
Diabetes mellitus (DM) yes yes no no (IFG) no (IFG)
Dyslipidemia IV IIb IV IV IIb
Steatosis no yes no no no
Arterial hypertension (AHT) yes yes no no yes




no no no yes no
Pancreatitis no no no no no










Weight (kg) 58.5 73.5 58.2 61.5 60.8
Height (cm) 157 159 161 165 160
BMI (kg/m2) 23.7 29.1 22.5 22.6 23.8
Waist (cm) 76 101 84 84 90
Hip (cm) 87 100 87 94 89
Waist-to-height ratio 0.9 1 1 0.9 1
Waist-to-hip ratio 0.48 0.64 0.52 0.51 0.56
Skinfold thickness (mm)
Triceps 5.5 5 16 20 6
Biceps 4 7 8 11 5
Suprailiac 9 18 23 24 11
Subscapular 17.5 34 28 52 28
Thigh 3.9 6 15 12 4
Calf 3.7 3 15 15 2
DXA scan, fat mass (g)
Fat % 21.3 31 38.6 38.9 28.9
Total fat 12,442 22,800 21,680 15,720 17,569
Upper-limb fat 993 2677 2757 2968 1991
Lower-limb fat 2454 4735 5383 6325 3151
Trunk fat 8040 14,446 12,734 15,452 11,601
Visceral fat 872 2070 871 1023 1247
Biochemical features
Basal glucose (mg/dL) 103 218 67 94 96
Hemoglobin A1c (%) 6.2 7.2 5.3 5,.2 5.7
Plasma insulin (mIU/l) 5.9 ND 20 57.8 13
Peptide C (ng/mL) ND 2.1 ND 3,4 2,2
Plasma leptin (ng/mL) 2.4 9.7 ND 13 3,3
Total cholesterol (mg/dL) 146 174 264 220 161
Plasma triglycerides (mg/dL) 372 247 214 338 151
High-density lipoprotein
cholesterol (HDLc) (mg/dL) 26 36 53 39 45


















9 57 23 23 14
Creatinine (mg/dL) 0.81 0.5 0.5 0.59 0.64
Creatine kinase (CK) ND 103 54 81 110
Thyroid stimulating
hormone (TSH) 1.43 2.02 2.78 3.27 3.58
Blood pressure (BP) 136/79 147/80 125/69 135/89 155/87
Echocardiogram



















“Obstetric complications” include miscarriages, gestational diabetes and/or macrosomy. IFG, impaired fasting glucose. ND, not determined.
SNP, single nucleotide polymorphisms.
3.1. Case Reports
Case #1 is a 53-year-old female (Figure 1A). She has suffered from Crohn’s disease
since her youth. The patient was diagnosed with FPLD when she was 42 years of age.
The lipodystrophic phenotype started during childhood and was characterized by the lack
of subcutaneous adipose tissue in limbs, abdomen and buttocks, rounded face, double
chin, and a hypermuscular appearance with calf hypertrophy, phlebomegaly and small
breasts. She did not have acanthosis nigricans, hirsutism nor cardiac disease (normal Holter
and echocardiography). At that age, she had a normal BMI (23.7 kg/m2), and reduced
skinfolds in limbs, but in normal range in trunk (Table 2). She had hepatomegaly, albeit
with normal glucose metabolism and no insulin resistance. On the other hand, she was
taking omega-3 fatty acids for hypertriglyceridemia and her plasma leptin levels were low.
At the age of 49, she was diagnosed with breast cancer and high blood pressure. At the
age of 52, she was diagnosed with diabetes mellitus, and at present she is on sitagliptin,
fenofibrate, n-3 fatty acids and telmisartan. Regarding her relatives, her mother (deceased)
and sister had a similar lipodystrophic phenotype. Moreover, her mother had diabetes,
hypertriglyceridemia, eruptive xanthomata, ischemic cardiopathy and suffered a stroke.
Her 59-year-old sister also had high blood pressure and was diagnosed with diabetes
mellitus when she was 52 years old, but she never came to the consultation for a medical
evaluation. However, her lipid profile was always normal. Both the proband and her sister
carry a heterozygous transition of cytosine to thymine in codon 1583 (exon 9) of the LMNA
gene, leading to a substitution of threonine for methionine in the highly conserved protein
residue 528. It was not possible to sequence the DNA of the deceased parents.
Case #2 is a 58-year-old female diagnosed with diabetes mellitus at the age of 44
(Figure 1B). She was referred to the Endocrinology Division due to a lipodystrophic
phenotype which began in childhood. She had fat loss in upper limbs, hips, thighs and
calves, as well as fat accumulation in the face with double chin, in the upper back and
the intra-abdominal region and scarce abdominal subcutaneous adipose panicle. Her
upper and lower limbs were muscular with phlebomegaly. Her hands were large with
thick fingers, and her calves were hypertrophied. There were no palpable lipomas. She
presented acanthosis nigricans on the nape and axillae, and also some acrochordons. She
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had high blood pressure, and hypertriglyceridemia. Her menstruation was regular and
did not suffer from fertility problems. She had no cardiovascular diseases. Abdominal
ultrasonography showed hepatomegaly (10–12 cm) with heterogeneous echostructure
and irregular margins, suggestive of non-alcoholic steatohepatitis and splenomegaly of
15 cm. At the age of 54, she was diagnosed with polyclonal hypergammaglobulinemia
and mild thrombocytopenia secondary to hepatopathy. A gastroscopy performed at the
age of 58 showed incipient esophageal varices. The patient referred that her deceased
mother, her daughter and two sisters had a similar phenotype, suggestive of familial partial
lipodystrophy. The mother and sisters had been diagnosed with diabetes mellitus. There
was no ischemic heart disease in her relatives.
Case #3 is the 34-year-old daughter of Case #2. At 31 years of age, she presented
an atypical, though not severe, FPLD phenotype with an androgenic distribution of fat
but no obvious fat loss (Figure 1C). There was fat accumulation in the face, double chin
and trunk (back and abdomen), but not in the hips, arms, buttocks or lower limbs. There
was no hypermuscularity or well-defined muscles, except for minimal hypertrophy of
the calves. The patient had no phlebomegaly. She claimed to have hyperphagia, and
she had no diabetes mellitus, no dyslipidemia, no hepatomegaly and no atherosclerotic
cardiovascular disease. At 34 years of age, she presented with hypertriglyceridemia and
low fat in the arms, buttocks, hips, and lower limbs, and accumulation of fat in the face,
double chin, trunk, abdomen, and axillae. She had a 2 cm lipoma on the right shoulder.
She did not manifest hirsutism, and acanthosis was minimal in the axillae. Her palms and
soles presented normal fat distribution, as did the rest of the physical examination.
Case #4 is a 20-year-old female who has presented an FPLD phenotype since adoles-
cence, with fat accumulation in the face, double chin, dorsal region, axillae, neck, arms and
scapular region (Figure 1D). The presence of fat was scarce in the hips, buttocks, thighs,
and calves. Fat was preserved in the abdomen. The patient presented phlebomegaly and
marked musculature but the hypertrophy of the calves was doubtful. The amount of fat in
her upper limbs was normal with no hypermusculation or phlebomegaly. She had acantho-
sis nigricans in the nape, axillae and groin. No lipomas were present. She had hirsutism,
and no alopecia. She had not developed diabetes mellitus or hypertension. Menarche
was at age 12, and oligomenorrhea/amenorrhea occurred before starting contraceptive
treatment. She suffered a pulmonary thromboembolism at age 19. There were no subjects
with diabetes in her family. Her father has hypertriglyceridemia and his lower limbs have
normal musculature. Her mother refused to be examined. A paternal aunt and a cousin
exhibited a similar phenotype. There was a significant history of cancer in her family:
Her paternal grandmother suffered from leukemia, a paternal cousin died at the age of
5 from leukemia, her paternal aunts suffered breast cancer and a paternal uncle died of
lung cancer.
Case #5 is a 62-year-old female who has presented a classic FPLD phenotype since
adolescence, with an absence of adipose tissue in the upper and lower limbs, buttocks
and hips, as well as an accumulation of fat on the face, abdomen, chin, back and axillae
(Figure 1E). Her musculature was well-defined in the arms, lower limbs and buttocks.
She had minimal phlebomegaly in her arms, frontotemporal alopecia and hirsutism in
her thighs. No lipomas or acanthosis were present. There was no hepatomegaly or
splenomegaly. She had a multinodular goiter. The patient did not suffer from diabetes
mellitus, but she did have hypertension, hyperlipidemia and muscle aches. At age 53,
she underwent a bypass for a revascularized heart disease. She had no fertility problems.
She claimed to have hyperphagia. Her father (deceased) exhibited a similar phenotype.
He had no diabetes mellitus nor heart disease. Her paternal grandmother also had a
similar phenotype.
The five cases studied are heterozygous for the variant c.1583C>T, p.(Thr528Met)
in the LMNA gene (rs57629361, ENST00000368300.8, NM_170707.2(LMNA):c.1583C>T).
This variant is classified as pathogenic according to ACMG guidelines (PM1, PM2, PM5,
PP2 y PP3) and its allele frequency in the European Non-Finnish (ENF) population is
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0.0021% (gnomAD). This variant was submitted just two times in ClinVar classified as
VUS (variant of uncertain significance), one of them without specific associated condition
in 2012 and the second one in 2020 associated to cardiomyopathy. In addition, Case #4
bears another variant in compound heterozygosis: c.[1583C>T];[1718C>T], p.(Thr528Met);
(Ser573Leu), the first variant inherited from her father and the second one from her
mother. The NM_170707.2(LMNA):c.1718C>T variant is classified as likely pathogenic
(PM1, PM2, PP2, PP3 and PP5). Its allele frequency in ENF population is 0.012% (gno-
mAD). This variant was reported nine times in ClinVar with classification ranging from
benign to pathogenic. Cases #2 and #3 are also heterozygous for the two rare variants:
c.1495A>G, p.(Arg499Gly) (chr8:30945355, transcript ENST00000298139.7) in the WRN
gene, and c.813C>G, p.(Lys271Asn) (chr15:91295027, transcript ENST00000355112.8) in
the BLM gene. The NM_000553.5(WRN):c.1495A>G variant is classified as VUS (PM2,
BP4). This rare variant was not found in any of the consulted databases (gnomAD and db-
SNP) although it was submitted once in ClinVar as a VUS in Werner syndrome. The
NM_000057.4(BLM):c.813C>G variant is also classified as VUS (PM2, BP4). It is nei-
ther found in genomic variant population databases consulted (dbSNP, gnomAD) nor
in Clinvar. Moreover, Case #1 is heterozygous for the non-synonymous polymorphism
c.34C>G, p.(Pro12Ala) in the PPARG gene (rs1801282, transcript ENST00000287820.10). The
NM_015869.4(PPARG):c.34C>G variant is classified as benign (PP2, BA1, BP4, BP6) and its
allele frequency in ENF population is 12.45% (gnomAD).
3.2. Cellular and Gene Expression Studies
Only partial differentiation was observed in control preadipocytes. These cells showed
no staining with Oil red O at basal level, although some cell clusters with lipid droplets
stained with Oil red O were evident after differentiation cocktail administration. However,
the preadipocytes obtained from Case #1 remained uncolored, failing to differentiate
(Figure 4).




Figure 4. Representative photographs of lipid droplet formation in preadipocytes demonstrated by using Oil red O stain-
ing. Preadipocytes were induced for differentiation over 10 days into adipocytes with the differentiation cocktail contain-
ing pioglitazone. At day 10, after the induction of adipogenic differentiation, microphotographs were taken from a central 
area of a representative triplicate well. Phase contrast microscopy images were visualized under 20-fold magnification; 4-
fold zoomed in areas are provided. 
Relative expressions of different genes involved in adipogenesis: CEBPA, CEBPB, 
FABP4, GLUT4, LPL and PPARG (Figure 5a–f), as well as PREF-1 as a preadipocyte marker 
(Figure 5g), were quantified by qPCR. As expected, the expression of PREF-1 was negligi-
ble in the fibroblasts culture (Figure 5g). The relative expressions of CEBPA, LPL and 
FABP4 were significantly reduced for the T528M preadipocytes when compared with the 
control preadipocytes (−76%, −59% and −95%, respectively). The relative expression of 
PPARG was significantly increased in T528M cells (+230%) when compared to control 
cells. Differences of expression for GLUT4 and CEBPB were not significant when compar-
ing T528M cells with control cells. After the differentiation process, there were significant 
differences in almost all the studied genes when comparing the control preadipocytes 
with the treated cells: PPARG, CEBPA, GLUT4, LPL and FABP4 were significantly in-
creased (+27%, +133%, +37%, +18421% and +1320%), whereas CEBPB was decreased 
(−22%). When comparing the relative gene expressions after treatment between control 
and T528M, there was an obvious decrease in T528M cells for CEBPA (−87%), LPL (−100%) 
and FABP4 (−96%). PPARG gene expression was significantly increased in T528M adipo-
cytes (+190%). 
Figure 4. Representative photographs of lipid droplet formation in preadipocytes demonstrated by using Oil red O staining.
Preadipocytes were induced for differentiation over 10 days into adipocytes with the differentiation cocktail containing
pioglitazone. At day 10, after the induction of adipogenic differentiation, microphotographs were taken from a central area
of a representative triplicate well. Phase contrast microscopy images were visualized under 20-fold magnification; 4-fold
zoomed in areas are provided.
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Relative expressions of different genes involved in adipogenesis: CEBPA, CEBPB,
FABP4, GLUT4, LPL and PPARG (Figure 5a–f), as well as PREF-1 as a preadipocyte marker
(Figure 5g), were quantified by qPCR. As expected, the expression of PREF-1 was negligible
in the fibroblasts culture (Figure 5g). The relative expressions of CEBPA, LPL and FABP4
were significantly reduced for the T528M preadipocytes when compared with the control
preadipocytes (−76%, −59% and −95%, respectively). The relative expression of PPARG
was significantly increased in T528M cells (+230%) when compared to control cells. Differ-
ences of expression for GLUT4 and CEBPB were not significant when comparing T528M
cells with control cells. After the differentiation process, there were significant differences
in almost all the studied genes when comparing the control preadipocytes with the treated
cells: PPARG, CEBPA, GLUT4, LPL and FABP4 were significantly increased (+27%, +133%,
+37%, +18421% and +1320%), whereas CEBPB was decreased (−22%). When comparing the
relative gene expressions after treatment between control and T528M, there was an obvious
decrease in T528M cells for CEBPA (−87%), LPL (−100%) and FABP4 (−96%). PPARG gene
expression was significantly increased in T528M adipocytes (+190%).




Figure 5. Relative expression of adipogenic genes. Relative expression of adipogenic genes: (A) PPARG, (B) CEBPA, (C) 
CEBPB, (D) GLUT4, (E) LPL and (F) FABP4; * p < 0.05 vs. Control, # p < 0.05 vs. T528M Basal, § p < 0.05 vs. Control Pio; and 
relative expression of the adipocyte marker (G) PREF-1, a: p < 0.001 vs. Fibroblast control, b: p < 0.05 vs. Control basal, c: p 
< 0.01 vs. T528M basal, d: p < 0.01 vs. Control Pio. All samples were analyzed in triplicate, n = 4. Results were normalized 
to the RNA polymerase II gene. 
Furthermore, the immunofluorescence staining of anti-prelamin A, anti-prelamin A 
cleaved farnesylated, anti-emerin and anti-lamin A/C was compared between control and 
T528M cells. Nuclear staining for prelamin A (non farnesylated), emerin and lamin A/C 
was similar between T528M and control preadipocytes when adding pioglitazone. The 
signal of farnesylated prelamin A was mildly more intense in the nuclear periphery and 
cytoplasm of T528 cells mainly before differentiation (Figure 6). 
Figure 5. Relative expression of adipogenic genes. Relative expression of adipogenic genes: (A) PPARG, (B) CEBPA,
(C) CEBPB, (D) GLUT4, (E) LPL and (F) FABP4; * p < 0.05 vs. Control, # p < 0.05 vs. T528M Basal, § p < 0.05 vs. Control
Pio; and relative expression of the adipocyte marker (G) PREF-1, a: p < 0.001 vs. Fibroblast control, b: p < 0.05 vs. Control
basal, c: p < 0.01 vs. T528M basal, d: p < 0.01 vs. Control Pio. All samples were analyzed in triplicate, n = 4. Results were
normalized to the RNA polymerase II gene.
Furthermore, the immunofluorescence staining of anti-prelamin A, anti-prelamin A
cleaved farnesylated, anti-emerin and anti-lamin A/C was compared between control and
T528M cells. Nuclear staining for prelamin A (non farnesylated), emerin and lamin A/C
was similar between T528M and control preadipocytes when adding pioglitazone. The
signal of farnesylated prelamin A was mildly more intense in the nuclear periphery and
cytoplasm of T528 cells mainly before differentiation (Figure 6).




Figure 6. Immunofluorescence images of representative preadipocytes and differentiated adipo-
cytes. All images were photographed at 20-fold magnification. 
4. Discussion 
FPLD2 or Dunnigan disease is a rare condition due to variants in the LMNA gene, 
usually affecting codons 8 to 11. This disorder is characterized by the lack of subcutaneous 
fat in the lower and upper limbs, buttocks and abdomen, and the presence of insulin re-
sistance with metabolic syndrome. We report five patients with the missense variant 
c.1583C>T, p.(Thr528Met) in exon 9 of LMNA, and various polymorphisms in LMNA and 
PPARG. Other variants in genes related to adipogenesis were ruled out. 
To this day, the p.(Thr528Met) change in LMNA has been associated with FPLD and 
progeroid syndromes albeit only in compound heterozygosity [1,2]. Savage et al. [1] pub-
lished the case of a female with FPLD2, who carried two LMNA missense variants: 
c.1748C>T (p.S583L) in exon 11, inherited from her father, and c.1583C>T, p.(Thr528Met) 
in exon 9, inherited from her mother. Relatives with only one of the changes did not ex-
hibit features of lipodystrophy, while those with both of them had the typical FPLD2 phe-
notype. In 2006, Verstraeten et al. [2] reported a male affected by a progeroid syndrome 
with two LMNA missense variants: c.1619T>C, p.(Met540Thr) in exon 10, inherited from 
his mother, and c.1583C>T p.(Thr528Met) in exon 9, inherited from his father. Although 
Figure 6. Immunofluorescence images of representative preadipocytes and differentiated adipocytes.
All images were photographed at 20-fold magnification.
4. Discussion
FPLD2 or Dunnigan disease is a rare condition due to variants in the LMNA gene,
usually affecting codons 8 to 11. This disorder is characterized by the lack of subcutaneous
fat in the lower and upper limbs, buttocks and abdomen, and the presence of insulin
resistance with metabolic syndrome. We report five patients with the missense variant
c.1583C>T, p.(Thr528Met) in exon 9 of LMNA, and various polymorphisms in LMNA and
PPARG. Other variants in genes related to adipogenesis were ruled out.
To this day, the p.(Thr528Met) change in LMNA has been associated with FPLD
and progeroid syndromes albeit only in compound heterozygosity [1,2]. Savage et al. [1]
published the case of a female with FPLD2, who carried two LMNA missense variants:
c.1748C>T (p.S583L) in exon 11, inherited from her father, and c.1583C>T, p.(Thr528Met)
in exon 9, inherited from her mother. Relatives with only one of the changes did not
exhibit features of lip dystrophy, while those with both of them ad the typical FPLD2
phenotype. In 2006, Verstraeten et al. [2] reported a mal affected b a progeroid syn-
drom with two LMNA missense variants: c.1619T>C, p.(Met540Th ) in exon 10, inher-
ited from his mother, and c.1583C>T p.(Thr528Met) in exon 9, inherited from his father.
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Although both parents did not suffer from any apparent disease, histological and molec-
ular investigations of their nuclei showed several abnormalities similar to those of the
son, albeit at a much lower frequency. Additionally, another variant in the same codon
of LMNA, c.1583C>G, p.(Thr528Arg), has been associated with Emery–Dreifuss muscu-
lar dystrophy [14]. Nucleotide changes in consecutive locus (c.1580G>A, p.(Ala527His);
c.1585G>A, p.(Ala529Thr); and c.1586C>T, p.(Ala529Val)) lead to type A mandibuloacral
dysplasia [15–17].
First, in this study, we show that the T528M variant could lead by itself to FPLD,
but with a variable lipoatrophic phenotype, ranging from obvious to subtle forms, not
as severe as in the case of exon 8 variants. It is unclear why earlier studies did not reach
similar results, but it should be borne in mind that variable expressiveness and incomplete
penetrance are common in Mendelian diseases. Other possibilities include the influence
of the environment, which might induce epigenetic changes or the presence of single
nucleotide polymorphisms (SNPs) in LMNA and/or other variants in other genes that
could explain the differences and modulate the pathogenic effect of the T528M variant.
Interestingly, the Pro12Ala polymorphism in PPARG found in Case #1 has been associated
with an inhibitory effect in thiazolidinedione-induced adipogenesis [18]. On the other
hand, the complications associated with the T528M variant do not seem so severe insofar
as there was only one case with ischemic heart disease and another with steatosis, although
it must be taken into account that the sample size is reduced. Hypertriglyceridemia was
present in all patients, but not as severe as in R482W patients, as there were no cases of
acute pancreatitis.
Secondly, cellular and gene expression studies support our findings in patients, that
is, the genotype-phenotype segregation for this LMNA variant, and that therefore the
T528M variant could alter adipogenesis. We found significant decreases in T528M cells
for CEBPA, LPL and FABP4 gene expressions. Lipoprotein lipase, which determines the
free fatty acid deposition in white adipose tissue, was almost undetectable in T528M cells,
as is the case of the adipocyte fatty acid binding protein 4, which is produced primarily
by adipocytes and whose blockade enhances insulin sensitivity. Moreover, the reduction
in CEBPA expression might indicate an alteration of the adipogenesis. Strikingly, PPARG
expression was significantly higher in T528M cells, whereas its expression is reduced in
the classic form of FPLD2 [19,20]. Recently, Oldenburg et al. (2017) demonstrated that the
R482W variant in LMNA inhibits adipogenesis by epigenetically deregulating long-range
enhancers of the anti-adipogenic miR335 microRNA gene in human adipocyte progenitor
cells [21]. As it is well known that PPARG is the master of adipogenesis, we speculate that
the T528M variant alters the adipogenic differentiation by different mechanisms and that
increased PPARG expression might be the reflection of a compensatory operating system.
If this change in PPARG expression could explain the not so severe lipoatrophic phenotype,
it would be a matter of speculation.
Regarding immunofluorescence studies, the mild increase in farnesylated prelamin A
in T528M cells might illustrate an intrinsic alteration in the lamin maturation, consistent
with previous studies on the pathogenesis of FPLD2 [20]. Even if the recent hypothesis
of the miRNA-related heterochromatin alterations is gaining more relevance, we have
to take into account that this was demonstrated only for the R482W variant [21], and it
cannot be ruled out that the accumulation of immature prelamin altering adipogenesis by
sequestering certain transcription factors as has been shown by other studies [20,22,23],
may play a role in the pathogenesis of lipodystrophy associated with the T528M variant.
However, this finding should be taken with caution, and further experiments in others
patients cell cultures would merit to be done in order to confirm this issue.
5. Conclusions
This work deepens the knowledge of laminopathies and lipodystrophies, and it
stresses the amazing complexity of these pathologies: The same disease may occur via
different variants and, in turn, the same variant can lead to different diseases. Although
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the results point to the direction that the T528M variant in LMNA could produce FPLD2 by
itself with a lipoatrophic phenotype varying from subtle to evident forms, we consider that
this study deserves further deepening.
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